Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD

 Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD

Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD

Shots:

  • OliX to receive $2.27M upfront, clinical milestones and royalties on sales of product. Thea to get license rights to develop & commercialize OLX301A in EU, Middle East and Africa (Ex- the US & Asia)
  • The focus of the agreement is to develop therapies based on OliX’s RNAi technology with the expansion of Thea’s Ophthalmology portfolio in retinal vascular diseases
  • OliX’s OLX301A is a novel therapy based on RNAi technology used for the development of ocular therapeutics and is currently evaluated in P-I trial for dry and wet age-related macular degeneration

Click here to read full press release/ article | Ref: Olix | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post